Verigat Tablet 5 mg contains Vericiguat, a modern soluble guanylate cyclase (sGC) stimulator used in the management of chronic heart failure with reduced ejection fraction (HFrEF). This higher-strength formulation is intended for patients who require dose escalation to achieve optimal therapeutic outcomes. Vericiguat improves heart function, reduces hospitalizations due to heart failure, and enhances overall quality of life in patients who remain symptomatic despite standard heart failure therapy.

Chronic heart failure is a condition in which the heart cannot pump sufficient blood to meet the body’s needs, leading to fatigue, shortness of breath, fluid retention, and reduced physical capacity. Vericiguat targets the underlying pathophysiology of heart failure by enhancing the nitric oxide (NO)-sGC-cGMP signaling pathway, promoting vasodilation, and improving cardiac efficiency.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Vericiguat works by stimulating soluble guanylate cyclase (sGC), an enzyme in the NO signaling pathway:

• Increases cyclic guanosine monophosphate (cGMP) levels, leading to relaxation of blood vessels

• Reduces vascular resistance, lowering afterload and blood pressure

• Enhances cardiac output and myocardial efficiency

• Decreases cardiac remodeling and stress on the heart

• Complements other standard heart failure medications to improve overall outcomes

This mechanism not only alleviates symptoms but also addresses disease progression in HFrEF.

Indications

Verigat Tablet 5 mg is indicated for:

• Treatment of chronic heart failure with reduced ejection fraction (HFrEF)

• Patients who remain symptomatic despite standard therapy including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists

• Reduction of heart failure-related hospitalizations

• Improvement of overall cardiovascular health and functional capacity

It is prescribed and monitored by cardiologists to ensure safe and effective therapy.

Dosage and Administration

• The usual starting dose of Verigat is 2.5 mg once daily, with dose escalation to 5 mg once daily based on tolerance and clinical response.

• Tablets should be taken orally, with or without food.

• Swallow the tablet whole with water; do not crush or chew.

• Regular monitoring of blood pressure, renal function, and symptoms of heart failure is recommended during treatment.

Consistent adherence to the prescribed dosage and follow-up is essential for optimal results.

Precautions

• Use under medical supervision, particularly in patients with hypotension, renal or hepatic impairment, or electrolyte disturbances.

• Inform your physician about all other medications being taken, as Vericiguat may interact with drugs affecting blood pressure or heart function.

• Not recommended during pregnancy or breastfeeding unless explicitly advised by a healthcare professional.

• Monitor for signs of dizziness or fainting due to low blood pressure.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Hypotension (low blood pressure)

• Dizziness or lightheadedness

• Headache

• Fatigue

Serious side effects are rare but may include worsening heart failure, syncope, or severe hypotension. Seek immediate medical attention if severe symptoms occur.

Storage

Store Verigat Tablet 5 mg in a cool, dry place, protected from light and moisture. Keep out of reach of children.

Verigat Tablet 5 mg provides an effective therapeutic option for patients with chronic heart failure, improving heart function, reducing hospitalizations, and enhancing overall quality of life as part of a comprehensive heart failure management plan.